OGEN - Oragenics Inc Stock Price, Fair Value and News

$0.86+0.01 (+1.18%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OGEN Price Action

Last 7 days

-5.5%

Last 30 days

-29.5%

Last 90 days

-18.9%

Trailing 12 Months

-91.0%

OGEN RSI Chart

OGEN Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

123.99

EV/EBITDA

0.66

Price/Free Cashflow

-0.43

OGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OGEN Fundamentals

OGEN Revenue

Revenue (TTM)

37.7K

OGEN Earnings

Earnings (TTM)

-10.9M

Earnings Growth (Yr)

-24.51%

Earnings Growth (Qtr)

-34.97%

OGEN Profitability

EBT Margin

-27445.56%

Return on Equity

-110.92%

Return on Assets

-85.83%

Free Cashflow Yield

-234.92%

OGEN Investor Care

Shares Dilution (1Y)

923.91%

Diluted EPS (TTM)

-10.47

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	133.5K	116.2K	37.7K	37.7K
2022	98.1K	109.3K	120.4K	131.5K
2021	0	0	0	87.0K
2020	827.5K	580.7K	333.8K	0
2016	1.1M	0	0	0
2015	1.1M	1.0M	1.2M	1.2M
2014	1.1M	1.2M	1.2M	939.9K
2013	1.1M	1.0M	1.0M	1.0M
2012	1.5M	1.4M	1.3M	1.3M
2011	1.3M	1.4M	1.4M	1.4M
2010	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Oragenics Inc

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

CEO	Ms. Kimberly M. Murphy
WEBSITE	oragenics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	6

Oragenics Inc Frequently Asked Questions

What is the ticker symbol for Oragenics Inc? What does OGEN stand for in stocks?

OGEN is the stock ticker symbol of Oragenics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oragenics Inc (OGEN)?

As of Wed Dec 03 2025, market cap of Oragenics Inc is 3.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OGEN stock?

You can check OGEN's fair value in chart for subscribers.

Is Oragenics Inc a good stock to buy?

The fair value guage provides a quick view whether OGEN is over valued or under valued. Whether Oragenics Inc is cheap or expensive depends on the assumptions which impact Oragenics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OGEN.

What is Oragenics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, OGEN's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 123.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oragenics Inc's stock?

In the past 10 years, Oragenics Inc has provided -0.64 (multiply by 100 for percentage) rate of return.